PARP inhibitors and their evolving role for the treatment of prostate cancer
PARP inhibitors and their evolving role for the treatment of prostate cancer
ALTA-1L: Brigatinib vs crizotinib for ALK advanced non small cell lung cancer patients
Breast cancer roundup from ESMO 2020
OncoAlert and ecancer weekly roundup for September 14-19, 2020
AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC
LungART: Radiotherapy after surgery for patients with non small cell lung cancer
Personalised molecularly matched therapies for carcinomas of unknown primary
SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer
The emerging importance of studying immune regulatory molecule expression patterns
OncoAlert and ecancer weekly roundup for September 6-13, 2020
Future directions of PARP inhibitors in prostate cancer
OncoAlert and ecancer weekly roundup for August 30 - September 5 2020